Price
No data yet.
Social Signal Score
Revenue
$7.7K-94.57%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy Mark Dyer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 2.00
- Country
- CH
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -109.80
Financials
Revenue
$7.7K-94.6%Net Income
$-1.71MEBITDA
$-1.70MFree Cash Flow
$-765.8KEPS (diluted)
$-1.20Shares Outstanding (diluted)
1.43M+1168.4%Operating Expenses
$398.7KCash & Debt
$937.5KReturn of Capital
$3.2KRevenue by Segment (annual)
$400.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $30.0K | $-6.73M | $-6.88 |
| 2024 | $404.1K | $7.06M | $8.40 |
| 2023 | $1.61M | $-10.56M | $-16.80 |
| 2022 | $1.42M | $-20.80M | $-55.20 |
| 2021 | $2.92M | $-15.35M | $-54.00 |
| 2020 | $3.61M | $-12.86M | $-57.60 |
| 2019 | $2.76M | $-14.78M | $-67.20 |
| 2018 | $6.04M | $-1.64M | $-8.47 |
| 2017 | $499.9K | $-3.28M | $-30.00 |
| 2016 | $17.3K | $-3.15M | $-33.60 |
| 2015 | $40.3K | $-4.20M | $-46.80 |
| 2014 | $85.4K | $-1.77M | $-21.60 |
| 2013 | $91.8K | $-14.46M | $-192.00 |
| 2012 | $121.1K | $-26.61M | $-403.20 |
Valuation
ADXNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
… extends cash runway to the fourth quarter 2027 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Mark…
View source ↗
Earnings
Mon, Nov 9(in 3 months)
Typical surprise -25.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Apr 30$-1.94 vs $-1.42miss
- Mon, Nov 10$-2.91 vs $-1.42miss
- Fri, Jun 20$-1.33 vs $-4.26beat
- Mon, Apr 7$-1.63 vs $-1.42miss
Estimates and results for ADXN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADXN officers and directors.
No open-market trades in the recent filings. All 17 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
17 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.